All In Biotech

Drug Trial Radar · NCT04772235

Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients

Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined With Osimertinib in Patients With Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).

Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

32

Planned (sponsor's estimate)

Start

Feb 11, 2022

Primary completion

Apr 2026

Study completion Jun 2026

Sponsor

Lead sponsor
Instituto Oncológico Dr RosellAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Turning Point Therapeutics, Inc.
First posted
Feb 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I study of repotrectinib in combination with osimertinib in patients with advanced or metastatic EGFR mutant non small cell lung cancer (NSCLC). The study will be conducted in 2 parts, Part Ia and Part Ib, and its purpose will be to find the incidence of dose-limiting toxicities (DLTs) as defined by the primary safety and tolerability endpoint. The Phase Ia study will also determine the impact of repotrectinib on osimertinib pharmacokinetics (PK) and the maximum tolerated dose (MTD), if reached, of repotrectinib given in combination with osimertinib and the recommended Phase II dose (RP2D). Dose escalation will be conducted according to a 'Rolling-6' based study design with 3 dose levels for repotrectinib: 80 mg once a day (QD), 160 mg QD or 160 mf QD during 14 days followed by 160 mg twice a day (BID); in combination with 80 mg QD of osimertinib. A total of 6 patients will be enrolled in each dose level cohort. In addition, this Phase Ib study will test early drug activity (efficacy) of the proposed combination treatment in an expansion cohort at the RP2D.

Conditions

  • Nsclc

Interventions

  • RepotrectinibDrug

    Repotrectinib will be taken orally once daily with or without food Part A: Dose escalation phase, with 3 dose levels for repotrectinib: (1) 80 mg QD, (2) 160 mg QD and (3) 160 mg QD for 14 days followed by 160 mg BID; in combination with 80 mg QD of osimertinib Part B: at the RP2D for all patients in combination with osimertinib.

  • OsimertinibDrug

    Osimertinib will be taken orally at 80 mg once daily with or without food. Part A: lead in dose in monotherapy at 80 mg QD during 14 days. In combination with repotrectinib afterwards. Depending on the safety and PK/ dose dependent interactions (DDIs) readout during the DLT assessment period, osimertinib dose may be adjusted. Part B: at the RP2D level in combination with repotrectinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs)Time frame: Throughout the study period. Approximately 48 months
  2. Incidence of Dose limiting toxicities (DLTs)Time frame: During the treatment cycle 1, 21 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario Gregorio Marañón

    Madrid, Spain · Recruiting

  • Hospital Regional Universitario de Málaga

    Málaga, Andalusia, Spain · Recruiting

  • Hospital Son Espases

    Palma, Balearic Islands, Spain · Recruiting

  • Quiron Dexeus

    Barcelona, Catalonia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.